
Search Clinical Trials
The BU-CTSI is a center of expertise providing tools, services and resources to clinical investigators, maximizing the impact of discoveries & speeding the translation of research into improved patient care
Sponsor Condition of Interest |
---|
Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups
Boston Medical Center
Vaccine Hesitancy
Vaccine Refusal
Achieving optimal vaccination rates is vital for protecting the health and well-being of
all individuals. This specific study focuses on the MMR and RSV vaccines in pregnancy and
early childhood, which have been shown to reduce RSV and MMR-related illnesses,
hospitalizations, and deaths. Efforts to1 expand
Achieving optimal vaccination rates is vital for protecting the health and well-being of all individuals. This specific study focuses on the MMR and RSV vaccines in pregnancy and early childhood, which have been shown to reduce RSV and MMR-related illnesses, hospitalizations, and deaths. Efforts to improve vaccination rates have not been equally effective across the entire population; this has resulted in poorer outcomes from interventions for certain populations who are vaccine-hesitant. This study seeks to understand how to best increase vaccine confidence in marginalized populations. To do this, the investigators will interview parents of children who receive care at Boston Medical Center (BMC), Community Health Workers and other Clinical providers at BMC, leading experts in the fields of vaccine confidence and implementation science, and key public health stakeholders/officials. Type: Observational Start Date: Jan 2025 |
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Novo Nordisk A/S
Sickle Cell Disease
This study is conducted to confirm whether etavopivat works well at reducing the number
of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood
vessels in adults and adolescents living with sickle cell disease. The study will also
evaluate how well etavopivat can red1 expand
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years. Type: Interventional Start Date: Feb 2025 |
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease1
Novo Nordisk A/S
Sickle Cell Disease, Thalassemia
Etavopivat is a new medicine under development for treating blood disorders like sickle
cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood
disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through
the body. This study is looking i1 expand
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country. Type: Interventional Start Date: Jan 2025 |
Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease
Harvard Medical School (HMS and HSDM)
Parkinson Disease (PD)
Freezing-of-gait (FoG) in Parkinson Disease (PD) is one of the most vivid and disturbing
gait phenomena in neurology. Often described by patients as a feeling of "feet getting
glued to the floor," FoG is formally defined as a "brief, episodic absence or marked
reduction of forward progression of th1 expand
Freezing-of-gait (FoG) in Parkinson Disease (PD) is one of the most vivid and disturbing gait phenomena in neurology. Often described by patients as a feeling of "feet getting glued to the floor," FoG is formally defined as a "brief, episodic absence or marked reduction of forward progression of the feet despite the intention to walk." This debilitating gait phenomena is very common in PD, occurring in up to 80% of individuals with severe PD. When FoG arrests walking, serious consequences can occur such as loss of balance, falls, injurious events, consequent fear of falling, and increased hospitalization. Wearable robots are capable of augmenting spatiotemporal gait mechanics and are emerging as viable solutions for locomotor assistance in various neurological populations. For the proposed study, our goal is to understand how low force mechanical assistance from soft robotic apparel can best mitigate gait decline preceding a freezing episode and subsequent onset of FoG by improving spatial (e.g. stride length) and temporal features (e.g. stride time variability) of walking. We hypothesize that the ongoing gait-preserving effects can essentially minimize the accumulation of motor errors that lead to FoG. Importantly, the autonomous assistance provided by the wearable robot circumvents the need for cognitive or attentional resources, thereby minimizing risks for overloading the cognitive systems -- a known trigger for FoG, thus enhancing the repeatability and robustness of FoG-preventing effects. Type: Interventional Start Date: Sep 2024 |
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and1
Hoffmann-La Roche
Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will
evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in
participants with moderately to severely active ulcerative colitis (UC). expand
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC). Type: Interventional Start Date: Sep 2024 |
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refrac1
Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose
levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent
Bruton tyrosine kinase (BTK) inh1 expand
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years. Type: Interventional Start Date: Jan 2025 |
Evaluating Interventions for Intimate Partner Violence Use in Washington State
Boston University
Intimate Partner Violence
Intimate partner violence (IPV), specifically physical and psychological aggression
toward an intimate partner, represents a public health crisis that affects millions of
Americans each year. There currently exists very little evidence from randomized
controlled trials for the effectiveness of abus1 expand
Intimate partner violence (IPV), specifically physical and psychological aggression toward an intimate partner, represents a public health crisis that affects millions of Americans each year. There currently exists very little evidence from randomized controlled trials for the effectiveness of abuser intervention programs designed to prevent and end perpetration of IPV in the general population. This is troubling considering that approximately half a million men and women are court-mandated to these programs each year. The investigators will conduct a randomized control trial (RCT) investigating the efficacy of the Strength at Home (SAH) intervention in reducing intimate partner violence (IPV). The overarching aim of this study is to test the efficacy of SAH with court-involved-partner-violent men through an RCT comparing those who receive SAH with those who receive other standard IPV interventions offered in the state of Washington (treatment as usual- TAU). The specific aims are: 1.1: Compare the frequency of physical and psychological IPV, the primary outcomes of interest, across conditions as reported by the male participants and their intimate partners across Time 1 (baseline) and four 3-month follow ups (Times 2-5). It is expected that greater reductions in IPV frequencies will be evidenced in SAH than TAU over the course of the year. 1.2: Compare symptoms of PTSD, alexithymia, and alcohol use problems across conditions and assessment time points as reported by the male participants. It is expected that greater reductions in these symptoms will be evidenced in SAH than TAU over the course of the year. 1.3: Compare treatment satisfaction across conditions as reported by the male participants across the four 3-month follow ups (Times 2-5). It is expected that treatment satisfaction will be higher in SAH than TAU. Type: Interventional Start Date: Nov 2024 |
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Bre1
Stemline Therapeutics, Inc.
Breast Cancer
The primary goal of this study is to evaluate the effectiveness of elacestrant versus
standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive
(ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high
risk of recurrence. expand
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence. Type: Interventional Start Date: Sep 2024 |
Simulation Trial of Telemedical Support for Paramedics
Boston Medical Center
Emergencies
Cardiopulmonary Arrest
Acute Respiratory Failure
Status Epilepticus
In the United States, the current standard of prehospital (i.e. outside of hospitals)
emergency care for children with life-threatening illnesses in the community includes
remote physician support for paramedics providing life-saving therapy while transporting
the child to the hospital. Most prehos1 expand
In the United States, the current standard of prehospital (i.e. outside of hospitals) emergency care for children with life-threatening illnesses in the community includes remote physician support for paramedics providing life-saving therapy while transporting the child to the hospital. Most prehospital emergency medical services (EMS) agencies use radio-based (audio only) communication between paramedics and physicians to augment this care. However, this communication strategy is inherently limited as the remote physician cannot visualize the patient for accurate assessment and to direct treatment. The purpose of this pilot randomized controlled trial (RCT) is to evaluate whether use of a 2-way audiovisual connection with a pediatric emergency medicine expert (intervention = "telemedical support") will improve the quality of care provided by paramedics to infant simulator mannequins with life threatening illness (respiratory failure). Paramedics receiving real-time telemedical support by a pediatric expert may provide better care due to decreased cognitive burden, critical action checking, protocol verification, and error correction. Because real pediatric life-threatening illnesses are rare, high stakes events and involve a vulnerable population (children), this RCT will test the effect of the intervention on paramedic performance in simulated cases of pediatric medical emergencies. The two specific aims for this research are: - Aim 1: To test the intervention efficacy by determining if there is a measurable difference in the frequency of serious safety events between study groups - Aim 2: To compare two safety event detection methods, medical record review, and video review Type: Interventional Start Date: Jul 2025 |
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relaps1
Kite, A Gilead Company
Multiple Myeloma
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene
autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory
multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38
monoclonal antibody and an immunomodulator1 expand
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM. Type: Interventional Start Date: Aug 2024 |
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Pati1
Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination
with standard of care anti-cancer drugs is more effective than standard of care in
participants with untreated advanced NSCLC. NSCLC must have a change in a gene called
KRAS G12C. Study participation, including f1 expand
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing. Type: Interventional Start Date: Dec 2023 |
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Pa1
AbbVie
Parkinson's Disease (PD)
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets
worse over time, but how quickly it progresses varies a lot from person to person. Some
symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this
study is to evaluate how effective ABBV1 expand
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to evaluate how effective ABBV-951 is in treating adult participants with advanced PD in real world setting. ABBV-951 (foslevodopa/foscarbidopa) is an approved drug for the treatment of Parkinson's Disease. The main ROSSINI study will have approximately 450 adult participants with PD (300 participants new to ABBV-951, up to 150 participants transitioning from open-label extension study) will be enrolled across approximately 60 sites. Decision to treat with ABBV-951 (or continue the treatment in Cohort B) will be made by the doctor prior to any decision to approach the participant to participate in this study. There will be a sub-study that will enroll 40 naïve participants who initiated Foslevodopa/Foscarbidopa treatment for the first time (Cohort A of the ROSSINI parent study only) from 6 to 15 centers in the United States, Germany and Spain. All participants will receive subcutaneous infusion of ABBV-951 for approximately 3 years. Participants will attend regular clinic visits during the course of the study. The effect of the treatment will be checked by medical assessments, and completing questionnaires. Type: Observational Start Date: Jan 2024 |
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
Boston University
HIV Infections
This is a 3-year study to test the efficacy of a text message-based intervention program.
Dental patients at 4 community health centers (n= 266) will be randomized to receive
either text messages (TMs) regarding HIV prevention or TMs regarding overall wellness.
Prior to enrolling the 266 participan1 expand
This is a 3-year study to test the efficacy of a text message-based intervention program. Dental patients at 4 community health centers (n= 266) will be randomized to receive either text messages (TMs) regarding HIV prevention or TMs regarding overall wellness. Prior to enrolling the 266 participants, the investigators will conduct a feasibility pilot (n=20) to test the TM delivery as well as all study procedures. For both the pilot and the randomized clinical trial (RCT), recruitment will be conducted at 4 Community Health Center dental clinics (Codman Square, East Boston (both East Boston and South End locations), Geiger Gibson, and Upham's Community Health Centers). Recruitment materials (flyers and permission to contact forms) may also be made available at other clinics within the health centers. The study will enroll English and Spanish-speaking patients who have at least one risk factor for HIV but are HIV-negative. Patients enrolled in the pilot will complete self-report surveys at baseline, 1 and 2 months. Participants enrolled in the RCT will complete self-report surveys baseline, 3, 6, and 12 months after baseline; receive and respond to TM assessments during the 6-month intervention. Type: Interventional Start Date: Aug 2024 |
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX1
Genentech, Inc.
Adenocarcinoma, Pancreatic Ductal
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene
cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan,
and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected
pancreatic ductal adenocarcinoma (PDAC)1 expand
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery. Type: Interventional Start Date: Oct 2023 |
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Novartis Pharmaceuticals
IC-MPGN
This study is designed as a multicenter, randomized, double-blind, parallel group,
placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in
idiopathic immune complex mediated membranoproliferative glomerulonephritis. expand
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis. Type: Interventional Start Date: Oct 2023 |
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or C1
Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1
and to further characterize safety and efficacy of an alternative dosing for teclistamab
in Part 2 in participants with relapsed or refractory multiple myeloma. expand
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma. Type: Interventional Start Date: Mar 2023 |
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal1
Janssen Research & Development, LLC
Carcinoma, Non-small-Cell Lung
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab
which will be administered as a co-formulation with recombinant human hyaluronidase PH20
(rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts
except Cohort 4) and to characteriz1 expand
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4). Type: Interventional Start Date: Nov 2022 |
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Rajshekhar Chakraborty, MD
AL Amyloidosis
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax
in combination with dexamethasone in participants with t(11;14) positive relapsed (comes
back) or refractory (did not get better) light chain amyloidosis. expand
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis. Type: Interventional Start Date: Oct 2022 |
(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds
Instylla, Inc.
Arterial Bleeding in Solid Organs and Peripheral Arteries
To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the
transcatheter embolization of peripheral arterial bleeds. expand
To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds. Type: Interventional Start Date: Dec 2022 |
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Janssen Research & Development, LLC
Amyloidosis
The purpose of this study is to characterize cardiac safety of Daratumumab,
Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A:
daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly
diagnosed systemic amyloid light chain (AL) amyloidosi1 expand
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethnic minorities, including Black or African American, with newly diagnosed AL amyloidosis treated with D-VCd (cohort 2). Type: Interventional Start Date: Mar 2022 |
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation1
NRG Oncology
Metastatic Lung Small Cell Carcinoma
Metastatic Malignant Neoplasm in the Brain
Recurrent Lung Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
This phase III trial compares the effect of stereotactic radiosurgery to standard of care
memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone
of the brain) for the treatment of small cell lung cancer that has spread to the brain.
Stereotactic radiosurgery is a s1 expand
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine. Type: Interventional Start Date: Jun 2021 |
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Michael J. Fox Foundation for Parkinson's Research
Parkinson Disease
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational,
multi-center natural history study to assess progression of clinical features, digital
outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD)
progression in study participants with manifest1 expand
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability. Type: Observational Start Date: Jul 2020 |
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Smal1
Genentech, Inc.
Non-small Cell Lung Cancer
This trial will evaluate the efficacy and safety of various therapies in patients with
Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung
cancer (NSCLC) tumors that meet protocol-specified biomarker criteria expand
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria Type: Interventional Start Date: Nov 2020 |
Impact of Balance Training in Community-Dwelling Older Adults After Recovery From COVID-19
Cairo University
Community-dwelling Older Adults
This research investigates the impact of balance training on improving functional
performance and reducing fall risk in community-dwelling older adults who have recovered
from COVID-19. Post-COVID-19, many elderly individuals experience lingering physical
impairments, including muscle weakness, dec1 expand
This research investigates the impact of balance training on improving functional performance and reducing fall risk in community-dwelling older adults who have recovered from COVID-19. Post-COVID-19, many elderly individuals experience lingering physical impairments, including muscle weakness, decreased coordination, and balance deficits, which increase their vulnerability to falls. The study evaluates whether a structured balance training program can enhance stability, mobility, and overall quality of life in this population. Type: Interventional Start Date: Jun 2025 |
BoTox Into the Sternocleidomastoid Muscles (SCM)
Boston Medical Center
Neck Muscle Issue
Botulinum toxin injections have been used both in the face and neck for many years.
However, injection into the sternocleidomastoid muscle (SCM) has only been done to treat
neck spasms. In this study botulinum toxin will be injected into the SCM to determine if
this will result in a temporary slimm1 expand
Botulinum toxin injections have been used both in the face and neck for many years. However, injection into the sternocleidomastoid muscle (SCM) has only been done to treat neck spasms. In this study botulinum toxin will be injected into the SCM to determine if this will result in a temporary slimming effect on the neck and produce a more feminine, youthful neck contour. Type: Interventional Start Date: May 2025 |
- Previous
- Next